Soligenix announces publication demonstrating enduring protection of its thermostable rivax® vaccine

Princeton, n.j., nov. 4, 2021 /prnewswire/ -- soligenix, inc. (nasdaq: sngx) (soligenix or the company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today publication of pre-clinical immunogenicity studies for rivax® (heat stable ricin toxin vaccine) demonstrating enduring protection for at least 12 months post-vaccination.
SNGX Ratings Summary
SNGX Quant Ranking